Xortx Therapeutics Stock Performance
| XRTX Stock | USD 1.21 0.02 1.68% |
The firm maintains a market beta of 0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, XORTX Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding XORTX Therapeutics is expected to be smaller as well. At this point, XORTX Therapeutics has a negative expected return of -0.35%. Please make sure to check out XORTX Therapeutics' kurtosis, as well as the relationship between the rate of daily change and market facilitation index , to decide if XORTX Therapeutics performance from the past will be repeated at some future point.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days XORTX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:9 | Last Split Date 2023-11-14 |
1 | Form 424B3 XORTX Therapeutics Inc. - StreetInsider.com | 09/24/2024 |
2 | XORTX Announces Presentation at the Rare and Genetic Disease Summit | 12/12/2024 |
| Begin Period Cash Flow | 10.4 M |
XORTX |
XORTX Therapeutics Relative Risk vs. Return Landscape
If you would invest 175.00 in XORTX Therapeutics on September 17, 2024 and sell it today you would lose (52.00) from holding XORTX Therapeutics or give up 29.71% of portfolio value over 90 days. XORTX Therapeutics is currently does not generate positive expected returns and assumes 6.36% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than XORTX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XORTX Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XORTX Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XORTX Therapeutics, and traders can use it to determine the average amount a XORTX Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0545
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XRTX |
Estimated Market Risk
| 6.36 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XORTX Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XORTX Therapeutics by adding XORTX Therapeutics to a well-diversified portfolio.
XORTX Therapeutics Fundamentals Growth
XORTX Stock prices reflect investors' perceptions of the future prospects and financial health of XORTX Therapeutics, and XORTX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XORTX Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.80 X | ||||
| EBITDA | (4.87 M) | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 13.42 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 11.51 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.09 X | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Earnings Per Share | 0.12 X | ||||
| Market Capitalization | 4.34 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (23.66 M) | ||||
| Working Capital | 3.77 M | ||||
| Current Asset | 341.74 M | ||||
| Current Liabilities | 109.37 M | ||||
About XORTX Therapeutics Performance
Evaluating XORTX Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if XORTX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XORTX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (590.60) | (620.13) | |
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (0.93) | (0.88) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.62) | (0.65) |
Things to note about XORTX Therapeutics performance evaluation
Checking the ongoing alerts about XORTX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XORTX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XORTX Therapeutics generated a negative expected return over the last 90 days | |
| XORTX Therapeutics has high historical volatility and very poor performance | |
| XORTX Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| XORTX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: XORTX Announces Presentation at the Rare and Genetic Disease Summit |
- Analyzing XORTX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XORTX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining XORTX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XORTX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of XORTX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XORTX Therapeutics' stock. These opinions can provide insight into XORTX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.